Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors*; D017209:Apoptosis; D051017:Apoptosis Regulatory Proteins; D015153:Blotting, Western; D053181:Caspase 8; D020169:Caspases / Q000378:metabolism; D002453:Cell Cycle; D016923:Cell Death; D002460:Cell Line; D045744:Cell Line, Tumor; D002986:Clinical Trials as Topic; D053138:Cyclohexenes; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D051231:Farnesyltranstransferase; D053222:Fas Ligand Protein; D005434:Flow Cytometry; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000378:metabolism; D008564:Membrane Potentials; D008928:Mitochondria / Q000378:metabolism*; D039821:Monoterpenes / Q000494:pharmacology; D009154:Mutation; D010950:Plasma Cells / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D015398:Signal Transduction; D053221:TNF-Related Apoptosis-Inducing Ligand; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D015854:Up-Regulation; D051020:bcl-X Protein
D051017:Apoptosis Regulatory Proteins; C494811:BCL2L1 protein, human; D053138:Cyclohexenes; D004791:Enzyme Inhibitors; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D039821:Monoterpenes; D019253:Proto-Oncogene Proteins c-bcl-2; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha; D051020:bcl-X Protein; C078706:perillic acid; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; C505530:CASP8 protein, human; D053181:Caspase 8; D020169:Caspases